Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Melatonin Treatment for Newborn Infants With Moderate to Severe Hypoxic Ischemic Encephalopathy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01904786
Recruitment Status : Withdrawn (Lack of enrollment of suitable candidates)
First Posted : July 22, 2013
Last Update Posted : July 3, 2015
Sponsor:
Information provided by (Responsible Party):
St. Louis University

Brief Summary:

During the birth process certain conditions can cause oxygen delivery and/or blood flow to the baby's brain to become interrupted. This can cause permanent brain damage. Brain damage occurs in two phases. The first occurs at the time of injury when brain cells in the affected area 'die'. There is nothing that can be done about this. The second phase of injury occurs over the next few days. This second phase is caused by inflammation and release of toxic chemicals from the injured site. Cooling the baby to a temperature of 92.5° F, for 3 days has been shown to reduce the second phase of injury and bran death. All babies will receive the benefit of cooling. Although cooling helps it does not completely stop the second phase of injury.

Melatonin is a naturally occurring hormone that is produced by the brain, and helps regulate the sleep-wake cycle. It has the potential to stop the second phase of brain injury by inhibiting inflammation and release of toxic chemicals. The reason for this research is to find out if melatonin can or cannot improve the outcome of babies with this kind of brain damage. Every baby enrolled in the study has a 50:50 chance of getting melatonin. A total of six doses of medicine will be given. The baby's brain function will be assessed by an EEG, brain oxygen monitoring, and a neurologic examination at 18 months of life. All of these are routinely used as part of standard care for patients with this kind of problem. The only difference is that half the babies enrolled in the study will get the drug called melatonin and the other half will receive placebo. The dose of melatonin being used in the study is higher than the amount normally produced by the body. No side-effects of this dose have been reported in other research studies using melatonin in newborn and premature babies.


Condition or disease Intervention/treatment Phase
Newborn Hypoxic Ischemic Encephalopathy Drug: Melatonin Drug: placebo Phase 1

Detailed Description:

This is a double-blind randomized study. All babies less than eight hours old, admitted to the NICU at Cardinal Glennon Children's Medical Center, with moderate to severe HIE that qualify for whole body cooling will be eligible for enrollment in the study. Whole body cooling is part of standard treatment for babies with moderate to severe HIE, and the criteria for diagnosis and cooling are well established. After consent is obtained babies will be randomly assigned to melatonin treatment or control groups (standard treatment) using a 4-block randomization design, by opening a sealed opaque sequentially numbered envelope by the study pharmacist. A log of assignments will be maintained by the study pharmacist. The clinical team will be blinded as to the assignment. Patients assigned to melatonin treatment will receive 40 mg melatonin (PureBulk, CA, USA) in 5 mL of vehicle (1:90 mix ethanol/saline) every 8 hours for a total of six doses. Patients assigned to the control group will receive 5 mL of vehicle only every 8 hours for a total of six doses. All doses will be administered via a nasogastric tube by the nurse assigned to the patient. Placement of a nasogastric tube is part of standard care for babies with HIE. Administration of the first dose within eight hours of life is mandatory for the study.

EEG analysis is part of standard neurologic evaluation for patients with HIE, and is done once the patient has been rewarmed to normal body temperature (by 78-80 hours after starting whole body cooling). A 24 hour multichannel video-EEG (Nihon Kohden 9100A, Nihon Kohden USA Inc.) using the 10-20 system of electrode placement modified for neonates will be performed between 80 and 100 hours after initiation of the cooling protocol. The duration of each seizure will be added together for the entirety of the recording to obtain the seizure burden (total seizure time).

Anticonvulsant treatment will assessed at the time of discharge whether the patient is on any, one, or more anticonvulsants.

Cerebral tissue oxygenation (rSO2) will be monitored non-invasively by applying the NIRS probe to the forehead and attaching it to the INVOS monitor (Somanetics, MI, USA). The probe is very similar to the oxygen saturation oximeter probe that is routinely used in newborns. Cerebral tissue oxygenation will be continuously monitored until re-warming is complete. Data will be collected at the start of monitoring and then every six hours.

A brain MRI is not required for the study, but if it is obtained then the results may be included in the data collected.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Melatonin Treatment for Newborn Infants With Moderate to Severe Hypoxic Ischemic Encephalopathy
Study Start Date : April 2014
Estimated Primary Completion Date : December 2017
Estimated Study Completion Date : November 2018

Resource links provided by the National Library of Medicine

Drug Information available for: Melatonin

Arm Intervention/treatment
Experimental: Melatonin
Melatonin 40 mg every 8 hours for a total of six doses given over 48 hours orally (per nasogastric tube).
Drug: Melatonin
Placebo Comparator: Placebo
Placebo consists of the solvent solution without melatonin. Solvent solution consists of 5 mL of saline/alcohol mixture in a ratio of 90:1
Drug: placebo



Primary Outcome Measures :
  1. Neurodevelopment at 18 months of life (BSID-III) [ Time Frame: 18 months ]
    The Bayley Scales of Infant Development III exam will be administered at 18 months of life to assess neurodevelopment.


Secondary Outcome Measures :
  1. Seizure burden [ Time Frame: Assessed on day 3-4 of life ]
  2. Reduction in Burst Suppression [ Time Frame: Assessed on day 3-4 of life ]
  3. Improved cerebral oxygenation [ Time Frame: First 3-4 days of life ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   up to 8 Hours   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Infants with moderate to severe hypoxic ischemic encephalopathy ≥36 weeks
  • First dose of study drug given within 8 hours of birth

Exclusion Criteria:

  • Major chromosomal or congenital defects

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01904786


Locations
Layout table for location information
United States, Missouri
Cardinal Glennnon Children's Medical Center
St. Louis, Missouri, United States, 63104
Sponsors and Collaborators
St. Louis University
Investigators
Layout table for investigator information
Principal Investigator: Farouk Sadiq, MD St. Louis University
Layout table for additonal information
Responsible Party: St. Louis University
ClinicalTrials.gov Identifier: NCT01904786    
Other Study ID Numbers: SLU22484
First Posted: July 22, 2013    Key Record Dates
Last Update Posted: July 3, 2015
Last Verified: January 2015
Keywords provided by St. Louis University:
Hypoxic Ischemic Encephalopathy
Newborn
Outcomes
Melatonin
Additional relevant MeSH terms:
Layout table for MeSH terms
Brain Diseases
Brain Ischemia
Hypoxia-Ischemia, Brain
Ischemia
Hypoxia
Pathologic Processes
Central Nervous System Diseases
Nervous System Diseases
Signs and Symptoms, Respiratory
Signs and Symptoms
Cerebrovascular Disorders
Vascular Diseases
Cardiovascular Diseases
Hypoxia, Brain
Melatonin
Antioxidants
Molecular Mechanisms of Pharmacological Action
Protective Agents
Physiological Effects of Drugs
Central Nervous System Depressants